Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefirix[®] (imlifidase) for desensitization treatment of highly sensitized kidney transplant patients
· Israel is the first market outside of Europe to grant regulatory approval for Idefirix[®] · The decision by Israel’s regulatory authority provides highly sensitized patients in Israel with the opportunity to receive Idefirix[®] as desensitization treatment · The approval to use Idefirix[®] as defined in indication approved by the European Medicines Agency (EMA)[1,2] Lund, Sweden and Petach Tikva, Israel March 28, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, and its partner Medison Pharma (“Medison”)